Pseudomonas aeruginosa: патогенность, патогенез и патология

Клиническая Микробиология и Антимикробная Химиотерапия. 2015; 17(3):170-186

​ Лазарева А.В., Чеботарь И.В., Крыжановская О.А., Чеботарь В.И., Маянский Н.А.
Pseudomonas aeruginosa синегнойная палочка вирулентность патогенез госпитальные инфекции
Раздел
Болезни и возбудители
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2015; 17(3):170-186

Аннотация

Синегнойная палочка (Pseudomonas aeruginosa) входит в число наиболее актуальных возбудителей оппортунистических инфекций. Настоящий обзор литературы содержит анализ публикаций, посвящённых молекулярной характеристике факторов вирулентности P. aeruginosa, а также патогенезу синегнойной инфекции, представляющему собой каскад сложных реакций между возбудителем и хозяином. Описаны разнообразные формы синегнойной патологии человека, включая полимикробную инфекцию с участием P. aeruginosa. Перечислены основные принципы диагностики, терапии и профилактики синегнойных инфекций.

Лазарева А.В.

ФГБНУ «Научный центр здоровья детей», Москва, Россия

Чеботарь Игорь Викторович

ФГБНУ «Научный центр здоровья детей», Москва, Россия

Крыжановская О.А.

ФГБНУ «Научный центр здоровья детей», Москва, Россия

Чеботарь В.И.

Нижегородская государственная медицинская академия, Нижний Новгород, Россия

Маянский Николай Андреевич

ФГБНУ «Научный центр здоровья детей», Москва, Россия
Первый Московский государственный медицинский университет им. И.М. Сеченова, Москва, Россия

  • 1. Rice L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: ESKAPE. J Infect Dis 2008; 197(8):1079-81.
  • 2. Kung V.L., Ozer E.A., Hauser A.R. The accessory genome of Pseudomonas aeruginosa. Microbiology and molecular biology reviews 2010; 74(4):621-41.
  • 3. Hancock R.E.W., Siehnel R., Martin N. Outer membrane proteins of Pseudomonas. Molecular microbiology 1990; 4(7):1069-75.
  • 4. May T.B., Shinabarger D., Maharaj R., Kato J., DeVault J.D., Chu L., et al. Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin microbiol rev 1991; 4(2):191-206.
  • 5. Маянский А.Н., Чеботарь И.В., Руднева Е.И., Чистякова В.П. Pseudomonas aeruginosa: характеристика биопленочного процесса. Молекулярная генетика, микробиология и вирусология 2012; 1:3-8.
  • 6. Flemming H.C. The perfect slime // Colloids and Surfaces. In: Biointerfaces 2011; 86(2):251-9.
  • 7. Turner J.M., Messenger A.J. Occurrence, biochemistry and physiology of phenazine pigment production. Advances in microbial physiology 1986; 27:211-75.
  • 8. Wahba A.H. Pyrorubrin-producing Pseudomonas aeruginosa. Applied microbiology 1965; 13(2):291-2.
  • 9. Cox C.D., Parker J. Use of 2-aminoacetophenone production in identification of Pseudomonas aeruginosa. J Сlin Microbiol 1979; 9(4):479-84.
  • 10. Visca P., Imperi F., Lamont I.L. Pyoverdine siderophores: from biogenesis to biosignificance. Trends in microbiology 2007; 15(1):22-30.
  • 11. Visca P., Ciervo A., Sanfilippo V., Orsi N. Iron-regulated salicylate synthesis by Pseudomonas spp. J Gen Microbiol 1993; 139:1995-2001.
  • 12. Giltner C.L., Van Schaik E.J., Audette G.F., et al. The Pseudomonas aeruginosa type IV pili receptor binding domain functions as an adhesin for both biotic and abiotic surfaces. Molecular microbiology 2006; 59(4):1083-96.
  • 13. Sato H., Okinaga K., Saito H. Role of pili in the pathogenesis of Pseudomonas aeruginosa burn infection. Microbiol Immunol 1988; 32:131-9.
  • 14. Heiniger R.W., Winther-Larsen H.C., Pickles R.J., Koomey M., Wolfgang M.C. Infection of human mucosal tissue by Pseudomonas aeruginosa requires sequential and mutually dependent virulence factors and a novel pilus-associated adhesion. Cellular Microbiol 2010; 12(8):1158-73.
  • 15. van Schaik E.J., Giltner C.L., Audette G.F., Keizer D.W., Bautista D.L., Slupsky C.M., et al. DNA binding: a novel function of Pseudomonas aeruginosa type IV pili. J Bacteriol 2005; 187(4):1455-64.
  • 16. Pier G.B. Pseudomonas aeruginosa lipopolysaccharide: A major virulence factor, initiator of inflammation and target for effective immunity. Int J Med Microbiol 2007; 297(5):277-95.
  • 17. Plotkowski M.C., Tournier J.M., Puchelle E. Pseudomonas aeruginosa strains possess specific adhesins for laminin. Infect Immun 1996; 64(2):600-5.
  • 18. Carnoy C., Scharfman A., Van Brussel E., Lamblin G., Ramphal R., Roussel P. Pseudomonas aeruginosa outer membrane adhesins for human respiratory mucus glycoproteins. Infection and Immunity 1994; 62(5):1896- 900.
  • 19. Arhin A., Boucher C. The outer membrane protein OprQ and adherence of Pseudomonas aeruginosa to human fibronectin. Microbiology 2010; 156(5):1415-23.
  • 20. Azghani A.O., Idell S., Bains M., Hancock R.E. Pseudomonas aeruginosa outer membrane protein F is an adhesin in bacterial binding to lung epithelial cells in culture. Microbial pathogenesis 2002; 33(3):109-14.
  • 21. Gilboa-Garber N., Avichezer D., Garber N.C. Bacterial lectins: properties, structure, effects, function and applications. In: Gabius H.-J., Gabius S. editors. Glycosciences: Status and perspectives. Germany: WileyVCH; 2002. p. 369-73.
  • 22. Caballero A.R., Moreau J.M., Engel L.S., Marquart M.E., Hill J.M., O’Callaghan R.J. Pseudomonas aeruginosa protease IV enzyme assays and comparison to other Pseudomonas proteases. Annal Biochem 2001; 290:330-7.
  • 23. Engel L.S., Hill J.M., Caballero A.R., Green L.C., O’Callaghan R.J. Protease IV, a unique extracellular protease and virulence factor from Pseudomonas aeruginosa. J Biol Chem 1998; 273:16792-7.
  • 24. Ostroff R.M., Vasil M.L. Identification of a new phospholipase C activity by analysis of an insertional mutation in the hemolytic phospholipase C structural gene of Pseudomonas aeruginosa. J Bacteriology 1987; 169(10):4597-601.
  • 25. Kоnig B., Jaeger K.E., Sage A.E., Vasil M.L., Kоnig W. Role of Pseudomonas aeruginosa lipase in inflammatory mediator release from human inflammatory effector cells (platelets, granulocytes, and monocytes). Infect Immun 1996; 64(8):3252-8.
  • 26. Morlon-Guyot J., Mеrе J., Bonhoure A., Beaumelle B. Processing of Pseudomonas aeruginosa exotoxin A is dispensable for cell intoxication. Infection and immunity 2009; 77(7):3090-9.
  • 27. Veesenmeyer J.L., Hauser A.R., Lisboa, T., Rello J. Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med 2009; 37(5):1777.
  • 28. Sato H., Frank D.W. ExoU is a potent intracellular phospholipase. Mol Microbiol 2004; 53(5):1279-90.
  • 29. Cigana C., Curcurù L., Leone M.R., Ieranò T., Lorè N.I., Bianconi I., et al. Pseudomonas aeruginosa exploits lipid A and muropeptides modification as a strategy to lower innate immunity during cystic fibrosis lung infection. PloS one 2009; 4(12):e8439.
  • 30. Grover S., Batish V.K., Srinivasan R.A. Production and properties of crude enterotoxin of Pseudomonas aeruginosa. Int J Food Microbiol 1990; 10(3):201-8.
  • 31. Williams H.D., Zlosnik J.E.A., Ryall B. Oxygen, cyanide and energy generation in the cystic fibrosis pathogen Pseudomonas aeruginosa. Adv Microb Physiol 2007; 52:1-71.
  • 32. Пыж А.Э., Никандров В.Н. Вклад сине-зеленых пигментов Pseudomonas aeruginosa в гемолитическую активность культуральной жидкости. Журн микробиол 2011; 1:19-25.
  • 33. Sadikot R.T., Blackwell T.S., Christman J.W., Prince A.S. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171(11):1209-23.
  • 34. Jenkins C.E., Swiatoniowski A., Power M.R., Lin T.J. Pseudomonas aeruginosa-induced human mast cell apoptosis is associated with up-regulation of endogenous Bcl-xS and down-regulation of Bcl-xL. J Immunology 2006; 177(11):8000-7.
  • 35. Cornelis P., Dingemans J. Pseudomonas aeruginosa adapts its iron uptake strategies in function of the type of infections. Front Cell Infect Microbiol 2013; 3(7):1-7.
  • 36. MacDonald I.A., Kuehn M.J. Stress-induced outer membrane vesicle production by Pseudomonas aeruginosa. J Bacteriol 2013; 195(13):2971-81.
  • 37. Чеботарь И.В., Маянский А.Н., Кончакова Е.Д. Нейтрофилы и биопленка: диалектика взаимоотношений. Журн микробиол 2013; 6:105-11.
  • 38. Кузнецова М.В., Николаева Н.В., Розанова С.М., Карпунина Т.И. Формирование биопленок нозокомиальными штаммами Pseudomonas aeruginosa. Журн микробиол 2011; 4: С. 8-148.
  • 39. Чеботарь И.В. Механизмы антибиоплёночного иммунитета. Вестник РАМН 2012; 12:22-9.
  • 40. Buret A., Ward, K.H. Olson, M.E., Costerton, J.W. An in vivo model to study the pathobiology of infectious biofilms on biomaterial surfaces. J biomedical materials research 1991; 25(7):865-74.
  • 41. Wingender J., Flemming H.C. The biofilm matrix. Nature Rev Microbiol 2010; 13:623-33.
  • 42. Gurung J., Khyriem A.B., Banik A., Lyngdoh W.V., Choudhury B., Bhattacharyya Р. Association of biofilm production with multidrug resistance among clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa from intensive care unit. Indian J Crit Care Med 2013; 17(4):214-8.
  • 43. Sanchez C.J., Mende K., Beckius M.L., Akers K.S., Romano D.R., Wenke J.C., Murray C.K. Biofilm formation by clinical isolates and the implications in chronic infections. BMC infectious diseases 2013; 13(1):47.
  • 44. Liang X., Pham X.Q.T., Olson M.V., Lory S. Identification of a genomic island present in the majority of pathogenic isolates of Pseudomonas aeruginosa. J Bacteriol 2001; 183(3):843-53.
  • 45. Singh G., Srinivasan R., Cheng J., Peng Z., Fujimura K., Baek M.S., et al. Rearrangement of a large novel Pseudomonas aeruginosa gene island in strains isolated from a patient developing ventilator-associated pneumonia. J Clin Microbiol 2014; 52(7):2430-8.
  • 46. Jimenez P.N., Koch G., Thompson J.A., Xavier K.B., Cool R.H., Quax W.J. The multiple signaling systems regulating virulence in Pseudomonas aeruginosa. Microbiology and Molecular Biology Reviews 2012; 76(1):46-65.
  • 47. Jakobsen T.H., Bjarnsholt T., Jensen P.O., Givskov M., Hоiby N. Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors. Future microbiology 2013; 8(7):901-21.
  • 48. Weng L., Zhang Y., Yang Y., Wang L. Isolation of the autoinducer-quenching strain that Inhibits LasR in Pseudomonas aeruginosa. Intern J Molecular Sciences 2014; 15(4):6328-42.
  • 49. Campodоnico V.L., Gadjeva M., Paradis-Bleau C., Uluer A., Pier G.B. Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. Trends in molecular medicine 2008; 14(3):120-33.
  • 50. Weinstein R.J., Young L.S. Neutrophil function in gram-negative rod bacteremia. The interaction between phagocytic cells, infecting organisms, and humoral factors. J Clinical Investigation 1976; 58(1):190-9.
  • 51. Lavoie E.G., Wangdi T., Kazmierczak B.I. Innate immune responses to Pseudomonas aeruginosa infection. Microbes and Infection 2011; 13(14):1133-45.
  • 52. Peterson P.K., Kim Y.O.U.N.G.K.I., Schmeling D.A.V.I.D., Lindemann M.A.R.J.O.R.I.E., Verhoef J., Quie P.G. Complement-mediated phagocytosis of Pseudomonas aeruginosa. J Lab Clin Med 1978; 92:883-94.
  • 53. Pier G.B., Ames P. Mediation of the killing of rough, mucoid isolates of Pseudomonas aeruginosa from patients with cystic fibrosis by the alternative pathway of complement. J Infect Diseases 1984; 150(2):223-8.
  • 54. Morrin M., Reen D.J. Inhibition of the adherence of Pseudomonas aeruginosa to epithelial cells by IgG subclass antibodies. J Medical Microbiology 1993; 39(6):459-66.
  • 55. Masinick S.A., Montgomery C.P., Montgomery P.C., Hazlett L.D. Secretory IgA inhibits Pseudomonas aeruginosa binding to cornea and protects against keratitis. Investigative ophthalmology & visual science 1997; 38(5):910-918.
  • 56. Hollsing A.E., Granström M., Vasil M.L., Wretlind B., Strandvik B. Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis. J Clin Microbiol 1987; 25(10):1868-74.
  • 57. Balachandran P. , Dragone L., Garrity-Ryan L., Lemus A., Weiss A., Engel J. The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence. J Clin Invest 2007; 117(2):419-27.
  • 58. Zweigner J., Schumann R.R., Weber J.R. The role of lipopolysaccharide-binding protein in modulating the innate immune response. Microbes Infect 2006; 8:946-52.
  • 59. Overhage J., Campisano A., Bains M., Torfs E.C., Rehm B.H., Hancock R.E. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 2008; 76(9):4176-82.
  • 60. Burton M.F., Steel P.G. The chemistry and biology of LL-37. Natural product reports 2009; 26(12):1572-84.
  • 61. Walker T.S., Tomlin K.L., Worthen G.S., Poch K.R., Lieber J.G., Saavedra M.T., et al. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun 2005; 73(6):3693-701.
  • 62. Robertson D.M., Parks Q.M., Young R.L., Kret J., Poch K.R., Malcolm K.C. et al. Disruption of contact lens-associated Pseudomonas aeruginosa biofilms formed in the presence of neutrophils. Invest Ophthalmol Vis Sci 2011; 52(5):2844-50.
  • 63. Mathee K., Ciofu O., Sternberg C., Lindum P.W., Campbell J.I., Jensen P. et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 1999; 145(Pt6):1349-57.
  • 64. Young R.L., Malcolm K.C., Kret J.E., Caceres S.M., Poch K.R., Nichols D.P., et al. Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. PLoS One 2011; 6(9): e23637.
  • 65. Driscoll J.A., Brody S.L., Kollef M.H. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007; 67(3):351-68.
  • 66. Lin M.F., Chen Y.L. Pseudomonas aeruginosa bacteremia: treatment and outcome-an analysis of 56 episodes. Infect Dis Clin Practice 2006; 14(3):150-3.
  • 67. Vitkauskienė A., Skrodenienė E., Dambrauskienė A., Macas A., Sakalauskas R. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality. Medicina (Kaunas) 2010; 46(7):490-5.
  • 68. Agodi A., Barchitta M., Cipresso R., Giaquinta L., Romeo M.A., Denaro C. Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients. Intensive care medicine. 2007; 33(7):1155-61.
  • 69. Руднов В.А., Бельский Д.В., Дехнич А.В., исследовательская группа РИОРИТа. Инфекции в ОРИТ России: результаты национального многоцентрового исследования. Клиническая Микробиология и Антимикробная Химиотерапия 2011; 13(4):294-304.
  • 70. Custovic A., Smajlovic J., Hadzic S., Ahmetagic S., Tihic N., Hadzagic H. Epidemiological surveillance of bacterial nosocomial infections in the surgical intensive care unit. Materia socio-medica 2014; 26(1):7-11.
  • 71. Nseir S., Martin-Loeches I., Makris D., Jaillette E., Karvouniaris M., Valles J., et al. Impact of appropriate antimicrobial treatment on transition from ventilatorassociated tracheobronchitis to ventilator-associated pneumonia. Crit Care 2014; 18(3): R129.
  • 72. Chastre J., Fagon J.Y. Ventilator-associated pneumonia. American J Respiratory Critical Care Medicine 2002; 165(7):867-903.
  • 73. Silva Filho L.V.R.F., Ferreira F.D.A., Reis F.J.C., Britto M.C.A.D., Levy C.E., Clark O., et al. Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment. J Brasileiro de Pneumologia 2013; 39(4):495-512.
  • 74. Gallego M., Pomares X., Espasa M., Castaner E., Solе M., Suаrez D., et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC pulmonary medicine 2014; 14(1):103.
  • 75. Mansoor T., Musani M.A., Khalid G., Kamal M. Pseudomonas aeruginosa in chronic suppurative otitis media: sensitivity spectrum against various antibiotics in Karachi. J Ayub Med Coll Abbottabad 2009; 21(2):120- 3.
  • 76. Nadel D.M., Lanza D.C., Kennedy D.W. Endoscopically guided cultures in chronic sinusitis. Am J Rhinol 1998; 12:233-41.
  • 77. Hazlett LD. Bacterial infections of the cornea (Pseudomonas aeruginosa). Chem Immunol Allergy 2007; 92:185- 94.
  • 78. Mittal R., Aggarwal S., Sharma S., Chhibber S., Harjai K. Urinary tract infections caused by Pseudomonas aeruginosa: а minireview. J Infect Public Health 2009; 2(3):101-11.
  • 79. Salmen P. , Dwyer D.M., Vorse H., Kruse W. Whirlpoolassociated Pseudomonas aeruginosa urinary tract infections. JAMA 1983; 250(15):2025-26.
  • 80. Sharma S., Kaur R., Yadav V., Harjai K., Joshi K. Contribution of exotoxin A of Pseudomonas aeruginosa in acute and chronic experimental renal infection. Jap J Infect Dis 2004; 57(3):119-20.
  • 81. Egan C.A., O’Reilly M.A., Meadows K.P. Relapsing Henoch-Schönlein purpura associated with Pseudomonas aeruginosa pyelonephritis. J American Academy of Dermatology 2000; 42(2):381-3.
  • 82. Wagenlehner F.M., Pilatz A., Bschleipfer T., Diemer T., Linn T., Meinhardt A., et al. Bacterial prostatitis. World J Urology 2013; 31(4):711-6.
  • 83. Kabiri M., Barkat A., El Ajaje H., Allali N., Dafiri R., Lamdouar-Bouazzaoui N. Neonatal epididymo-orchitis caused by Pseudomonas aeruginosa: a case report. Cases Journal 2010; 3(1):44.
  • 84. Augustin P., Tran-Dinh A., Valin N., Desmard M., Crevecoeur M.A., Muller-Serieys C., et al. Pseudomonas aeruginosa post-operative peritonitis: clinical features, risk factors, and prognosis. Surg Infect 2013; 14(3):297- 303.
  • 85. Yaita K., Sameshima I., Takeyama H., Matsuyama S., Nagahara C., Hashiguchi R., et al. Liver abscess caused by multidrug-resistant Pseudomonas aeruginosa treated with colistin; a case report and review of the literature. Intern Medicine (Tokyo, Japan) 2012; 52(12):1407-12.
  • 86. Carek P.J., Dickerson L.M., Sack J.L. Diagnosis and management of osteomyelitis. Am Fam Physician 2001; 63(12):2413-20.
  • 87. Фоминых С.Г. Раневые инфекции: значение микробиологического мониторинга при составлении больничного формуляра антимикробных препаратов. Клиническая Микробиология и Антимикробная Химиотерапия 2011; 13(4):368-75.
  • 88. Андреева С.В., Бахарева Л.И., Нохрин Д.Ю. Видовой состав микрофлоры ожоговых ран пациентов Челябинского областного ожогового центра. Вестник Челябинского государственного университета 2013; 7:58-9.
  • 89. Guggenheim M., Zbinden R., Handschin A.E., Gohritz A., Altintas M.A., Giovanoli P. Changes in bacterial isolates from burn wounds and their antibiograms: a 20-year study (1986-2005). Burns 2009; 35(4):553-60.
  • 90. Calhoun J.H., Murray C.K., Manring M.M. Multidrugresistant organisms in military wounds from Iraq and Afghanistan. Clinical Orthopaedics and Related Research 2008; 466(6):1356-62.
  • 91. Yu Y., Cheng A.S., Wang L., Dunne W.M., Bayliss S.J. Hot tub folliculitis or hot hand-foot syndrome caused by Pseudomonas aeruginosa. J American Academy of Dermatology 2007; 57(4):596-600.
  • 92. Wu D.C., Chan W.W., Metelitsa A.I., Fiorillo L., Lin A.N. Pseudomonas Skin Infection. Amer J Clinical Dermatology 2011; 12(3):157-69.
  • 93. Lota A.S., Altaf F., Shetty R., Courtney S., Mckenna P., Iyer S. A case of necrotising fasciitis caused by Pseudomonas aeruginosa. J Bone & Joint Surgery, British Volume 2010; 92(2):284-5.
  • 94. Müller S., Ebnöther M., Itin P. Green nail syndrome (Pseudomonas aeruginosa Nail Infection): two cases successfully treated with topical nadifloxacin, an acne medication. Case reports in dermatology 2014; 6(2):180.
  • 95. Thomsen T.R., Aasholm M.S., Rudkjоbing V.B., Saunders A.M., Bjarnsholt T., Givskov M., et al. The bacteriology of chronic venous leg ulcer examined by culture-independent molecular methods.Wound repair and regeneration 2010; 18(1):38-49.
  • 96. Adlard P.A., Kirov S.M., Sanderson K., Cox, G.E. Pseudomonas aeruginosa as a cause of infectious diarrhoea. Epidemiology and Infection 1998; 121(1):237-41.
  • 97. Chuang C.H., Wang Y.H., Chang H.J., Chen H.L., Huang Y.C., Lin T.Y., et al. Shanghai fever: a distinct Pseudomonas aeruginosa enteric disease. Gut 2014; 63(5):736-43.
  • 98. Bassetti M., Righi E., Viscoli C. Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy? Curr Med Chem 2008; 14:517-22.
  • 99. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
  • 100. Hattemer A., Hauser A., Diaz M., Scheetz M., Shah N., Allen J.P., et al. Bacterial and clinical characteristics of health care-and community-acquired bloodstream infections due to Pseudomonas aeruginosa // Antimicrob Ag Chemotherapy 2013; 57(8):3969-75.
  • 101. Pena C., Cabot G., Gomez-Zorrilla S., Zamorano L., Ocampo-Sosa A., Murillas J., et al. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin Infect Dis 2014: ciu 866 [Epub ahead of print].
  • 102. Dantas R.C., Ferreira M.L., Gontijo-Filho P.P., Ribas R.M. Pseudomonas aeruginosa bacteremia: independent risk factors for mortality and impact of resistance on outcome. J Medical Microbiology 2014: jmm. 0.073262-0 [Epub ahead of print].
  • 103. Kirschke D.L., Jones T.F., Craig A.S., Chu P.S., Mayernick G.G., Patel J.A., et al. Pseudomonasaeruginosa and Serratia marcescens contamination associated with a manufacturing defect in bronchoscopes. New England J Medicine 2003; 348(3):214-20.
  • 104. Gibson J., Sood A., Hogan D.A. Pseudomonas aeruginosa — Candida albicans interactions: localization and fungal toxicity of a phenazine derivative. Applied and environmental microbiology 2009; 75(2):504-13.
  • 105. Leclair L.W., Hogan D.A. Mixed bacterial-fungal infections in the CF respiratory tract. Medical Mycology 2010; 48(Suppl 1):125-32.
  • 106. Hogan D.A., Kolter R. Pseudomonas – Candida interactions: an ecological role for virulence factors. Science 2002; 296(5576):2229-32.
  • 107. Morales D.K., Grahl N., Okegbe C., Dietrich L.E., Jacobs N.J., Hogan D.A. Control of Candida albicans metabolism and biofilm formation by Pseudomonas aeruginosa phenazines. MBio 2013; 4(1): e00526.
  • 108. Trejo-Hernández A., Andrade-Domínguez A., Hernández M., Encarnación S. Interspecies competition triggers virulence and mutability in Candida albicansPseudomonas aeruginosa mixed biofilms. The ISME journal 2014; 8(10):1974-88.
  • 109. Lindsay A.K., Morales D.K., Liu Z., Grahl N., Zhang A., Willger S.D., et al. Analysis of Candida albicans mutants defective in the Cdk8 module of mediator reveal links between metabolism and biofilm formation. PLoS genetics 2014; 10(10):1004567.
  • 110. Маянский А.Н., Чеботарь И.В., Евтеева Н.И., Руднева Е.И. Межвидовое общение бактерий и образование смешанной (полимикробной) биоплёнки. Журн микробиол 2012; 1:93-101.
  • 111. Aliaga L., Mediavilla J.D., Llosa J., Miranda C., RosaFraile M. Clinical significance of polymicrobial versus monomicrobial bacteremia involving Pseudomonas aeruginosa. Europ J Clinical Microbiol Infectious Dis 2000; 19(11):871-4.
  • 112. Pastar I., Nusbaum A.G., Gil J., Patel S.B., Chen J., Valdes J. et al. Interactions of methicillinresistant Staphylococcus aureus USA300 and Pseudomonas aeruginosa in polymicrobial wound infection. PloS one 2013; 8(2):56846.
  • 113. Hobbs R.D., Downing S.E., Andriole V.T. Four-valve polymicrobial endocarditis caused by Pseudomonas aeruginosa and Serratia marcescens. American J Medicine 1982; 72(1):164-8.
  • 114. Qadri S.M.H., Khalil S.H. Polymicrobial septicemia due to Shigella flexneri and Pseudomonas aeruginosa: first report. J National Medical Association 1987; 79(12):128-1292.
  • 115. Bovo R., Benatti A., Ciorba A., Libanore M., Borrelli M., Martini A. Pseudomonas and Aspergillus interaction in malignant external otitis: risk of treatment failure.ACTA Otorhinolaryngologica Italica 2012; 32(6):416-9.
  • 116. Korman T.M., Grayson M.L., Turnidge J.D. Polymicrobial septicaemia with Pseudomonas aeruginosa and Streptococcus pyogenes following traditional tattooing. J Infection 1997; 35(2):203.
  • 117. Крыжановская О.А., Лазарева А.В., ПономаренкоО.А., Катосова Л.К., Тепаев Р.Ф., КарасеваО.В., Чеботарь И.В. Масс-спектрометрическая идентификация возбудителей инфекций кровотока: опыт в педиатрической практике. Росс педиатрический журнал 2014; 17(5):4-9.
  • 118. Погорелов А.Г., Чеботарь И.В., Погорелова В.Н. Изучение микробной биопленки на внутренней поверхности катетера методом сканирующей электронной микроскопии. Клеточные технологии в биологии и медицине 2014; 2:133-6.
  • 119. Marra A.R., Bearman G.M., Wenzel R.P., Edmond M.B. Comparison of the systemic inflammatory response syndrome between monomicrobial and polymicrobial Pseudomonas aeruginosa nosocomial bloodstream infections. BMC Infect Dis 2005; 5(1):94.
  • 120. Чеботарь И.В., Маянский А.Н., Кончакова Е.Д., Лазарева А.В., Чистякова В.П. Антибиотикорезистентность биоплёночных бактерий. Клиническая Микробиология и Антимикробная Химиотерапия 2012; 14(1):51-8.
  • 121. Agodi A., Barchitta M., Cipresso R., Giaquinta L., Romeo M.A., Denaro C. Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients. Intens Care Med 2007; 33(7):1155-61.
  • 122. Traugott K.A., Echevarria K., Maxwell P. , Green K., Lewis J.S. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy. 2011; 31(6):598-608.
  • 123. Paul M., Leibovici L. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. Infect Dis Clin North Am 2009; 23(2):277-93.
  • 124. Bae Y., Lee G.M., Sim J.H., Lee S., Lee S.Y., Park Y.L. Green nail syndrome treated with the application of tobramycin eye drop. Ann Dermatology 2014; 26(4):514-16.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились